PTC Wins FDA Approval For First Brain-Delivered Gene Therapy Kebilidi
Kebilidi represents the 13th gene therapy to score an FDA nod, but it's the first gene therapy to be administered directly in the brain.
Kebilidi represents the 13th gene therapy to score an FDA nod, but it's the first gene therapy to be administered directly in the brain.
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™️ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) Read Full Story
Despite mixed results in testing, agency officials determined Elevidys showed enough to warrant a label that includes all patients at least 4 years of…
Conshohocken, PA, October 24, 2023 – Sequoia Reinsurance Services and IOA Re are pleased to announce a collaboration with Everest Reinsurance Company (“Everest”) and/or its affiliates to expand their…
The high cost of healthcare claims is just one of several market challenges facing self-insured employers today. The cost of preventable hospital-acquired conditions adds…
Beyond being a major public health challenge, obesity carries extreme implications for employers and their teams. In fact, a recent report estimates obesity cost…
The U.S. Food and Drug Administration said on Monday it had approved the use of Gamida Cell Ltd's (GMDA.O), opens new tab cell therapy for…
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic…
Feb 16 (Reuters) - Iovance Biotherapeutics (IOVA.O), opens new tab said on Friday the U.S. health regulator has granted an accelerated approval for its cell therapy…
he FDA has approved Vertex and CRISPR's gene-editing therapy Casgevy to treat beta thalassemia. Casgevy becomes the first therapy for the rare blood disorder…